Lonza's Half-Year Results for 2025 highlight a period of strong financial and operational performance, with an optimistic revised outlook for its core Contract Development and Manufacturing Organisation (CDMO) business. The company is actively implementing a new, streamlined operating model that became effective in April 2025, impacting how its diverse business areas are structured and reported.
• Discover how Lonza's CDMO business showcased impressive growth, leading to an upward revision of its outlook for the remainder of 2025
• Uncover the recovery trajectory of the Capsules & Health Ingredients business, which is progressing as anticipated despite the ongoing preparations for its strategic exit
• Explore the varied performance across Lonza's newly formed Integrated Biologics, Advanced Synthesis, and Specialized Modalities platforms, with some areas achieving significant advancements while others navigated temporary challenges
